University of California, San Francisco
San Francisco, California, 94107, United States
Location status: Recruiting
Location contact
James T McCracken, MD
PRINCIPAL_INVESTIGATOR
Starlette Khim, BA
CONTACT
NCT Number: NCT07065669
This is a pilot study to examine the tolerability, safety and early efficacy of two forms of transcranial magnetic stimulation (TMS) for treating adolescents with Obsessive Compulsive Disorder (OCD) who have experienced limited improvements with usual treatments for OCD in adolescents.
The project's primary goal is to examine whether adolescents can complete 3 consecutive weeks of TMS administered 5 days per week, and to describe the type of and how common individual side effects with TMS occur in adolescents with OCD.
Participants will:
* visit the clinic every weekday for 3 weeks (15 days) to receive TMS treatments * have a brain MRI scan before TMS treatments begins and after finishing all TMS * complete questionnaires and report changes in behavior and physical symptoms
Interested in participating?
Request Info13 year–17 year
All sexes
Interventional
Not applicable
San Francisco, California, 94107, United States
Location status: Recruiting
James T McCracken, MD
PRINCIPAL_INVESTIGATOR
Starlette Khim, BA
CONTACT
This study's primary goal is to examine whether treatment with two forms of transcranial magnetic stimulation (TMS) called theta burst stimulation (TBS) show acceptable tolerability, safety, and preliminary signals of efficacy for adolescents with Obsessive Compulsive Disorder (OCD) that has not responded satisfactorily to 1st line treatments. While TMS is FDA-approved for OCD in adults, data on TMS in youth with OCD is limited. Results will inform on how suitable TMS treatment is for adolescents with OCD, and guide future, larger studies.
The study is considered a randomized, single blind, clinical trial.
The design of the study is a two-group parallel comparative study of two different TMS stimulation sites, the orbito-frontal cortex (OFC) and the dorsal medial prefrontal cortex (dmPFC).
Model description: both groups will receive active TMS treatment sessions in clinic every weekday for 3 consecutive weeks (15 days). During each TMS session, participants in both groups will receive 3 TMS stimulations separated by a rest period, for a total of 45 individual TMS treatments. Study participants will receive TMS to only their assigned stimulation site.
Number of arms: there are two treatment arms based on assigned treatment site, an OFC arm and a dmPFC arm.
Masking: an independent evaluator will be masked to treatment arm assignment and adverse events. All other study personnel will not be masked.
Allocation: participants will be randomly assigned to group according to a computer-generated assignment schedule.
Enrollment: total planned enrollment is 30 eligible participants who are randomized.
Arm Information:
Arm titles-- orbitofrontal cortex (OFC) and dorsal medial prefrontal cortex (dmPFC) Arm types: the dmPFC arm is considered the intervention arm; the OFC arm is considered the active comparator arm.
Interventions:
Intervention type: Device (both arms)
Intervention name(s):
OFC - continuous theta burst stimulation (cTBS) dmPFC - intermittent theta burst stimulation (iTBS)
Intervention description:
OFC - three stimulations per day of 1,800 pulses/stimulation cTBS for 15 days dmPFC - three stimulations per day of 1,800 pulses/session iTBS for 15 days
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
iTBS stimulation of the dmPFC is a FDA-approved treatment for adults with OCD
continuous theta burst stimulation (cTBS) 1,800 pulses per session
Time frame: Baseline to completion of all protocol visits, up to 8 weeks
Proportion (percentage) of all participants who enter the study, undergo a minimum of one TMS treatment, and complete the protocol-specified 15 TMS visits
Time frame: Baseline to completion of all protocol visits up to 8 weeks
Frequency (percentage) of individual adverse events
Time frame: Baseline to completion of all protocol visits, up to 8 weeks
Change in independent assessor-rated CY-BOCS II total score
Time frame: From screening to end of treatment (Week 4)
Compare changes in blinded clinician CY-BOCS II total by TMS site (OFC vs dmPFC)
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07347405
Anxiety Disorders, Mental Disorders
Tucson, Arizona, United States
View Trial DetailsNCT07701616
Anxiety Disorders, Mental Disorders
Changsha, Hunan, China
View Trial DetailsNCT06376734
Anxiety Disorders, Behavior
Sunnyvale, California, United States
View Trial DetailsNCT07704632
Anxiety Disorders, Mental Disorders
Toronto, Ontario, Canada
View Trial Details